Today's Updates
Could timing prostate cancer radiotherapy according to patients’ circadian rhythm genes reduce the risk for late side effects?
Progression-free survival with the multitarget PAM inhibitor approaches 10 months after anti-CDK4/6 and aromatase inhibitor failure.
Researchers retrospectively analyzed outcomes for 50 patients with biopsy-proven monoclonal gammopathy of renal significance for a median follow-up of 6.15 years.
In a small single-center study, 1-year survival is 100% among carefully selected patients who undergo bilateral lung transplantation for stage IV disease confined to the lungs.
Oncology
Review of tumor microenvironment readiness as a predictor of cancer progression and clinical outcomes.
Comprehensive review on immune surveillance screening for early cancer risk detection in clinical practice.
Comprehensive review of enhancing early immune surveillance for cancer prevention, with clinical evidence, mechanisms, and guideline-based insights.
Review of evolving oncology education in the age of targeted therapies for clinicians.
Dr. Harish P and 1 more
Dr. Vijay Agarwal and 1 more
Dr Suvir Singh
Dr Vijay Agarwal and 1 more
Dr. Todd Bauer and 1 more
Dr. Poonam Patil and 1 more
Fastest Growing Medical Platform for Doctors
Address : Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone : +1-415-463-3094
Email : anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
To get started please enter your email ID
By entering your details you agree to our
Please check your email for the four-digit security code and enter it below.
Didn't receive a code? Resend OTP
Join to enhance your clinical skills and gain specialized in-depth medical knowledge
Country
State
64824 This Month
2524 Today